<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104344">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099461</url>
  </required_header>
  <id_info>
    <org_study_id>20130349</org_study_id>
    <nct_id>NCT02099461</nct_id>
  </id_info>
  <brief_title>Effect of Amgen Investigational Product on Cellular Biomarkers in the Human Breast</brief_title>
  <official_title>A Randomized, Stratified, Open-label, No-treatment-controlled, Parallel Group, Multicenter Phase 1 Trial to Evaluate the Effect of Denosumab on Cellular Proliferation in the Human Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to enroll 72 healthy female volunteers. Subjects will be randomized into 1
      of 3 treatment arms.  The impact of the Investigational Prodcuct on relevant cellular
      biomarkers in the human breast will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Ratio of post-baseline to baseline Ki-67 index</measure>
    <time_frame>Approximately 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ratio of post-baseline to baseline Ki-67 index</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteer, Female, Breast</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No Investigational Product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose of low-dose denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose of high-dose denosumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>No investigational product will be administered</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab - low dose</intervention_name>
    <description>Single SC dose</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab - high dose</intervention_name>
    <description>Single SC dose</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Willing to use, in combination with her partner, 2 non-hormonal methods of effective
             contraception or practice sexual abstinence. Subjects who are surgically sterile (eg,
             history of hysterectomy) or whose sexual partner is sterile (eg, history of
             vasectomy) are not required to use contraceptive measures

          -  Laboratory tests are within clinically acceptable range

          -  Clinically acceptable physical exam and no history or evidence of any clinically
             significant medical disorder that would pose a risk to subject safety or interfere
             with study evaluations or procedures.

        EXCLUSION CRITERIA:

          -  Female subject with a prior history of breast cancer; Breast implant in the breast to
             be biopsied; Known history of fibrocystic breast disease

          -  Subject is unable or unwilling to provide breast biopsy tissue from the upper outer
             quadrant of her breast

          -  Pregnant or plans to become pregnant while exposed to investigational product

          -  Lactating/breastfeeding or plans to breastfeed while exposed to investigational
             product

          -  Recent use of any non-approved medications or devices

          -  Uncontrolled thyroid disorder

          -  Significant dental/oral disease

          -  Planned invasive dental procedures

          -  Positive urine screen for alcohol and/or drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
